In Vivo Activation of mINK Cells with INKmuneTM – Results from a Phase I-IIClinical Trial in Patients with Metastatic, Castration-Resistant Prostate Cancer
Time: 11:00 am
day: Day 1 - Track B - AM
Details:
- Discussing interim clinical results from using a tumor cell “psuedokine” to activate and recruit NK cells to target solid tumors in vivo
- Highlighting key considerations when moving NK trials from tertiary to secondary clinical Settings
